Product category: Rapid tests - clinical chemistry, Point of care - testing systems
Diabetes screening Diab spot is a non-invasive test to identify people at risk for diabetes or pre-diabetes without overnight fasting, a blood draw, or waiting for a lab result.
Diabetes mellitus is now one of the most common diseases globally with an estimated 285 million affected persons worldwide and 344 million persons with pre-diabetes. Each year, another 7 million people develop diabetesI and 3.8 million deaths worldwide are linked directly to diabetes related causes. The estimate is that at least one third of the patients with diabetes is undiagnosed.
Diabetes complications are very common. A large proportion of diabetics (50% or more in some studies) have at least one complication present at the time of diagnosis. In order to reduce diabetes associated complications and mortality there is a great need for screening and monitoring methods to assess the risk of diabetes and diabetic complications. If (pre-)diabetes is detected early, with only lifestyle intervention, or with medication the development of diabetes and its complications can be postponed or even prevented.
Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess cardiovascular risk and risk of diabetes. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader - a state of art diagnostic device which can determine the tissue accumulation of AGEs in 12 seconds.
AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important cardiovascular risk predictor. The AGE Reader measurements allows the doctor to adjust the treatment for high-risk patients as soon as possible.